导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.56% | 4076/4773 |
| 近一周 | -1.07% | 4632/5517 |
| 近一月 | -3.86% | 2285/5427 |
| 近一季 | 3.99% | 674/5241 |
| 近半年 | -12.68% | 3972/4939 |
| 近一年 | -17.73% | 3925/4404 |
| 近两年 | 4.85% | 2844/2955 |
| 近三年 | -25.53% | 2193/2255 |
| 成立以来 | 261.52% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.90% 3722/4961 |
-14.15% 4555/5312 |
- - |
- - |
| 2025 | -4.94% 3366/4813 |
-0.95% 2488/3635 |
-3.60% 3452/4076 |
3.48% 3740/4524 |
-3.78% 3338/4813 |
| 2024 | 0.12% 2087/3463 |
-0.05% 1065/2808 |
-8.47% 2242/3014 |
16.71% 1374/3129 |
-6.22% 2636/3463 |
| 2023 | -19.70% 1861/2656 |
1.33% 1594/2280 |
-14.61% 2240/2385 |
-0.41% 419/2515 |
-6.81% 1930/2655 |
| 2022 | -15.06% 408/2207 |
-20.16% 1524/1919 |
19.26% 92/2016 |
-11.53% 540/2113 |
0.82% 1444/2208 |
| 2021 | -3.66% 922/1822 |
-9.17% 1102/1255 |
10.81% 433/1330 |
-10.13% 1213/1466 |
6.51% 214/1822 |
| 2020 | 95.12% 18/1250 |
4.35% 76/1028 |
28.37% 107/1067 |
19.89% 66/1164 |
21.51% 52/1184 |
| 2019 | 53.60% 80/1092 |
31.26% 209/754 |
13.30% 1/804 |
0.25% 539/850 |
3.03% 846/918 |
| 2018 | -17.30% 128/834 |
- - |
- - |
- - |
-12.55% 456/691 |
| 2017 | 46.60% 13/714 |
- - |
- - |
- - |
- - |
| 2016 | 2.48% 82/605 |
- - |
- - |
- - |
- - |
| 2015 | 26.77% 85/575 |
- - |
- - |
- - |
- - |
| 2014 | 15.13% 199/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4796 | 32.41% |
| 港股通药 | 0.9109 | 32.37% |
| 万家中证港股通创新药ETF | 1.6293 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6918 | 32.17% |
| 天弘恒生沪深港创新药精选50ETF | 0.8599 | 32.08% |
| 港股医疗 | 0.9703 | 31.90% |
| 港医疗 | 0.9212 | 31.83% |
| 港股通医疗ETF工银 | 0.9798 | 31.81% |
| 港股通医疗ETF华宝 | 0.9918 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4193 | 31.06% |
| 华夏消费ETF VS. 长安沪深300非周期A(740101) |